[Form 4] iTeos Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Lee David K, a director of iTeos Therapeutics, Inc. (ITOS), reported transactions dated 08/29/2025 related to company stock options in connection with the merger of the company with Concentra Merger Sub VIII, Inc. The filing notes two option entries showing dispositions: 21,141 and 23,625 stock options with an exercise price of $9.84 that were reported as disposed. The Form 4 explains that, under the Merger Agreement, outstanding unvested options tied to certain service or severance arrangements became immediately vested and exercisable, while in-the-money options with exercise prices below the cash consideration per share of $10.047 were canceled in exchange for cash consideration and contractual contingent value rights.

Positive

• Accelerated vesting for eligible unvested options occurred, making those awards immediately exercisable as described in the Merger Agreement
• Cash consideration was provided for canceled in-the-money options, ensuring immediate cash value to option holders

Negative

• In-the-money options were canceled rather than preserved, removing potential future upside tied to the company as an independent public entity
• Reported dispositions total 44,766 options which could affect post-transaction equity interests and beneficial ownership disclosures

Insights

Financial Analyst

TL;DR: Form 4 shows merger-driven option accelerations and cancellations that convert option value into immediate cash and contingent value rights, a routine merger outcome.

The filing documents option dispositions tied directly to the Merger Agreement. Two option lots totaling 44,766 options are reported as disposed and reflect the standardized treatment where in-the-money options were canceled for cash consideration and CVRs while certain awards accelerated and became exercisable. For investors, this is a mechanical equity-treatment event rather than an operational development; it clarifies dilution and immediate cash payouts to option holders.

Corporate Governance Expert

TL;DR: Disclosure details equity award treatment on change of control: accelerated vesting for eligible awards and cancellation-for-cash for in-the-money options.

The Form 4 provides transparent mapping of how the Compensation and Leadership Development Committee implemented the Merger Agreement provisions. It confirms accelerated vesting for awards subject to specified employment or severance arrangements and the contractual mechanism that converted in-the-money options into cash and contingent value rights, which is consistent with typical M&A equity settlement practices.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee David K

(Last) (First) (Middle)

C/O ITEOS THERAPEUTICS, INC.

321 ARSENAL STREET

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iTeos Therapeutics, Inc. [ ITOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.84	08/29/2025		D(1)(2)			21,141	(1)(2)(3)	(1)(2)(3)	Common Stock	21,141	(1)(2)(3)	0	D
Stock Option (Right to Buy)	$9.84	08/29/2025		D(3)			23,625	(3)	(3)	Common Stock	23,625	(3)	0	D

Explanation of Responses:

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 18, 2025, by and among iTeos Therapeutics, Inc. (the "Company"), Concentra Biosciences LLC ("Parent"), and Concentra Merger Sub VIII, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Parent completed a tender offer for shares of common stock of the Company ("Shares") and thereafter, the Merger Sub merged with and into the Company (the "Merger"). Pursuant to the actions of the of the Compensation and Leadership Development Committee of the Board of Directors of the Company and in accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each option to purchase Shares from the Company ("Company Stock Options," and each such option, a "Company Stock Option")

2. (Continued from footnote 1) that was then outstanding but not then vested or exercisable and that was held by a Company service provider who was subject to an individual employment or other agreement and/or a Company severance and change in control plan or agreement that provides for accelerated vesting of time-based equity awards upon the occurrence of a sale of the Company or a qualifying termination of employment or service in connection with, or within a specified time following, a sale of the Company became immediately vested and exercisable in full.

3. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, by virtue of the Merger and without any action on the part of the holders, each Company Stock Option that had an exercise price per share that is less than the $10.047 in cash per share ("Cash Amount") (each, an "In-the-Money Option") that was then outstanding was canceled and, in exchange therefor, the holder of such canceled In-the-Money Option became entitled to receive in consideration of the cancellation of such In-the-Money Option (x) an amount in cash without interest, subject to any applicable tax withholding, equal to the product obtained by multiplying (1) the excess of the Cash Amount over the exercise price per Share underlying such In-the-Money Option by (2) the number of Shares underlying such In-the-Money Option as of immediately prior to the Effective Time and (y) one non-transferable contractual contingent value right for each Share underlying such In-the-Money Option.

	/s/ Adi Osovsky, as Attorney-in-Fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lee David K report on Form 4 for ITOS?

The filing reports option dispositions dated 08/29/2025, showing 21,141 and 23,625 stock options disposed, tied to the company merger.

Why were iTeos stock options canceled or converted in this Form 4?

Per the Merger Agreement, in-the-money Company stock options with exercise prices below the $10.047 cash per-share consideration were canceled in exchange for cash consideration and contractual contingent value rights.

Did any options become immediately exercisable due to the merger?

Yes. The filing states that options that were outstanding but not then vested or exercisable and that were held by service providers subject to qualifying agreements became immediately vested and exercisable in full.

How many options are reported as disposed in this filing?

The Form 4 reports dispositions totaling 44,766 options (21,141 and 23,625), each with an exercise price of $9.84.

What is the cash per-share amount referenced in the Form 4?

The filing references a $10.047 cash per-share amount used to determine cancellation consideration for in-the-money options.